HC Wainwright Issues Optimistic Outlook for DNTH Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Dianthus Therapeutics to a loss of $1.00 per share from a projected loss of $1.43, while maintaining a “Buy” rating and $158 price target.
• Dianthus reported a quarterly loss of $0.90 per share, missing the $0.85 consensus estimate, although revenue of $0.76 million exceeded expectations of $0.30 million. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $124.27.
• The clinical-stage biotech remains unprofitable, and recent insider selling—including the CEO’s sale of 166,000 shares worth about $17.9 million—could weigh on investor sentiment despite institutional investors owning approximately 47.5% of the stock.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Equities researchers at HC Wainwright lifted their Q3 2026 EPS estimates for Dianthus Therapeutics in a note issued to investors on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.00) for the quarter, up from their previous forecast of ($1.43). HC Wainwright has a "Buy" rating and a $158.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($3.83) per share. HC Wainwright also issued estimates for Dianthus Therapeutics' Q4 2026 earnings at ($1.11) EPS, FY2026 earnings at ($3.87) EPS, Q1 2027 earnings at ($1.26) EPS, Q2 2027 earnings at ($1.39) EPS, Q3 2027 earnings at ($1.51) EPS, Q4 2027 earnings at ($1.62) EPS, FY2027 earnings at ($5.77) EPS, FY2028 earnings at ($7.60) EPS, FY2029 earnings at ($0.13) EPS and FY2030 earnings at $10.75 EPS.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million.

Other equities analysts have also recently issued research reports about the company. Truist Financial increased their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Guggenheim reissued a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reissued a "buy" rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Raymond James Financial restated a "strong-buy" rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $124.27.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $108.92 on Monday. Dianthus Therapeutics has a twelve month low of $18.08 and a twelve month high of $114.55. The firm has a market capitalization of $5.95 billion, a PE ratio of -26.25 and a beta of 1.22. The firm's 50-day moving average price is $94.72 and its 200 day moving average price is $80.90.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company's stock worth $280,000 after purchasing an additional 618 shares during the period. American Century Companies Inc. increased its holdings in Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company's stock worth $1,009,000 after purchasing an additional 6,323 shares during the period. Invesco Ltd. raised its position in Dianthus Therapeutics by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company's stock valued at $390,000 after purchasing an additional 4,962 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company's stock valued at $21,887,000 after buying an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $27,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company's stock, valued at $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Marino Garcia sold 166,000 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the sale, the chief executive officer owned 65,292 shares of the company's stock, valued at $7,058,718.12. This represents a 71.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 253,779 shares of company stock valued at $25,931,495 in the last ninety days. 3.02% of the stock is currently owned by company insiders.

Key Stories Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target for Dianthus Therapeutics to $158 from $130 and maintained a “Buy” rating. The target implies additional upside and reflects the firm’s long-term expectations for the company’s complement-therapy pipeline. Dianthus Therapeutics Price Target Raised to $158
• Positive Sentiment: HC Wainwright improved several near- and long-term earnings forecasts, including narrowing its estimated 2026 loss to $3.87 per share from $4.81 and projecting a return to profitability by 2030 at $10.75 per share. The firm continues to rate DNTH “Buy” with a $158 target. HC Wainwright Dianthus Therapeutics estimates
• Positive Sentiment: Institutional interest has expanded, led by BlackRock’s approximately $402 million new position. Institutional investors now own about 47.5% of the stock, which may reinforce investor confidence and liquidity. Dianthus Therapeutics institutional ownership and insider trading
• Neutral Sentiment: Analyst views are generally favorable but not unanimous. DNTH has a “Moderate Buy” consensus, with 12 Buy ratings and one Sell rating; the average price target is $124.27, below HC Wainwright’s $158 objective. Analysts conflicted on Dianthus Therapeutics
• Negative Sentiment: CEO Marino Garcia sold 166,000 shares for approximately $17.9 million, reducing his direct holdings by 71.8%. Although the sale may be part of personal financial planning, its size can weigh on sentiment, particularly after the stock’s strong advance. Dianthus Therapeutics CEO stock sale
• Negative Sentiment: The company remains loss-making and recently missed quarterly EPS expectations, reporting a $0.90 loss per share versus an expected $0.85 loss. Revenue exceeded estimates, but the result highlights continued execution and funding risks for this clinical-stage biotech.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source